Chimera Bioengineering's Convertible Note Round

Chimera Bioengineering raised a round of funding on July 26, 2017. Investors include Illumina Accelerator.

Chimera Bioengineering is a biotherapeutics company building RNA based gene regulatory systems for chimeric antigen receptor CAR-T cell therapeutics with greater efficacy against solid tumors.…

Articles about Chimera Bioengineering's Convertible Note Round: